Shelton Capital Management’s Pacific Biosciences PACB Stock Holding History

Shelton Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-282,100	Closed	-$1.64M	–	721
2022 Q3	$1.64M	Sell	282,100 -47,900	-15%	-$275K	0.08%	211
2022 Q2	$1.46M	Buy	330,000 +230,000	+230%	+$1.4M	0.07%	230
2022 Q1	$910K	Sell	100,000 -35,000	-26%	-$403K	0.03%	281
2021 Q4	$2.76M	Hold	135,000	–	–	0.1%	207
2021 Q3	$3.45M	Buy	135,000 +44,000	+48%	+$1.3M	0.13%	168
2021 Q2	$3.18M	Buy	91,000 +29,000	+47%	+$843K	0.12%	184
2021 Q1	$2.06M	Buy	62,000 +43,000	+226%	+$1.51M	0.07%	237
2020 Q4	$493K	Buy	+19,000	New	+$323K	0.02%	349

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Shelton Capital Management's PACB Position: Q4 2022 in Review

Shelton Capital Management sold out of Pacific Biosciences (PACB) in Q4 2022, closing a stake of 282,100 shares — an estimated $1.64M sold.

Shelton Capital Management first reported a position in PACB in Q4 2020 and held it in 8 quarters. The position peaked at $3.45M in Q3 2021. 236 funds tracked by Wall St. Rank hold PACB as of Q4 2022.

Shelton Capital Management reported no remaining Pacific Biosciences position as of Q4 2022 after selling out during the quarter.
Shelton Capital Management sold 282,100 Pacific Biosciences shares in Q4 2022, an estimated $1.64M.
Shelton Capital Management first reported a position in Pacific Biosciences in Q4 2020 and held it in 8 quarters.
Shelton Capital Management's Pacific Biosciences position peaked at $3.45M in Q3 2021.
236 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2022.

Based on Shelton Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.